PGM
URGN icon

Parian Global Management’s UroGen Pharma URGN Stock Holding History

Parian Global Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,482
Closed -$537K – 23
2018
Q4 		$537K Buy
+12,482
New +$561K 0.44% 15

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parian Global Management's URGN Position: Q1 2019 in Review

Parian Global Management sold out of UroGen Pharma (URGN) in Q1 2019, closing a stake of 12,482 shares — an estimated $537K sold.

Parian Global Management first reported a position in URGN in Q4 2018 and held it in 1 quarter. The position peaked at $537K in Q4 2018. 74 funds tracked by Wall St. Rank hold URGN as of Q1 2019.

  • Parian Global Management reported no remaining UroGen Pharma position as of Q1 2019 after selling out during the quarter.
  • Parian Global Management sold 12,482 UroGen Pharma shares in Q1 2019, an estimated $537K.
  • Parian Global Management first reported a position in UroGen Pharma in Q4 2018 and held it in 1 quarter.
  • Parian Global Management's UroGen Pharma position peaked at $537K in Q4 2018.
  • 74 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2019.

Based on Parian Global Management's 13F filing for Q1 2019, filed 15 May 2019.